Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth E Palmer

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
AIDS Research and Human Retroviruses|July 29, 2011
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in miceKaustuv Banerjee, Elizabeth Michael, Dirk Eggink, et al.
Plos One|August 11, 2011
Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidateJoseph Calvin Kouokam, Dana Huskens, Dominique Schols, et al.
Antimicrobial Agents and Chemotherapy|August 24, 2016
Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV InfectionTiffany N Grooms, Hung R Vuong, Kevin M Tyo, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2013
Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent modelsChristopher Barton, J Calvin Kouokam, Amanda B Lasnik, et al.
Communications Medicine|April 9, 2024
Dynamic SARS-CoV-2 surveillance model combining seroprevalence and wastewater concentrations for post-vaccine disease burden estimatesRochelle H Holm, Grzegorz A Rempala, Boseung Choi, et al.
Vaccine|May 27, 2006
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopesKenneth E Palmer, Ann Benko, Sarah A Doucette, et al.
AAPS Pharmscitech|February 24, 2021
Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV PreventionLindsay F Kramzer, Krystal T Hamorsky, Phillip W Graebing, et al.
Medrxiv : the Preprint Server for Health Sciences|January 19, 2023
Wastewater and seroprevalence for pandemic preparedness: variant analysis, vaccination effect, and hospitalization forecasting for SARS-CoV-2, in Jefferson County, KentuckyRochelle H Holm, Grzegorz A Rempala, Boseung Choi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 13, 2026
Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2Raghuram Kandimalla, Farrukh Aqil, Divyasha Saxena, et al.
Vaccines|November 27, 2021
CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated ImmunopathologyJennifer K DeMarco, Joshua M Royal, William E Severson, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
AIDS Research and Human Retroviruses|July 29, 2011
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in miceKaustuv Banerjee, Elizabeth Michael, Dirk Eggink, et al.
Plos One|August 11, 2011
Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidateJoseph Calvin Kouokam, Dana Huskens, Dominique Schols, et al.
Antimicrobial Agents and Chemotherapy|August 24, 2016
Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV InfectionTiffany N Grooms, Hung R Vuong, Kevin M Tyo, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2013
Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent modelsChristopher Barton, J Calvin Kouokam, Amanda B Lasnik, et al.
Communications Medicine|April 9, 2024
Dynamic SARS-CoV-2 surveillance model combining seroprevalence and wastewater concentrations for post-vaccine disease burden estimatesRochelle H Holm, Grzegorz A Rempala, Boseung Choi, et al.
Vaccine|May 27, 2006
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopesKenneth E Palmer, Ann Benko, Sarah A Doucette, et al.
AAPS Pharmscitech|February 24, 2021
Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV PreventionLindsay F Kramzer, Krystal T Hamorsky, Phillip W Graebing, et al.
Medrxiv : the Preprint Server for Health Sciences|January 19, 2023
Wastewater and seroprevalence for pandemic preparedness: variant analysis, vaccination effect, and hospitalization forecasting for SARS-CoV-2, in Jefferson County, KentuckyRochelle H Holm, Grzegorz A Rempala, Boseung Choi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 13, 2026
Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2Raghuram Kandimalla, Farrukh Aqil, Divyasha Saxena, et al.
Vaccines|November 27, 2021
CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated ImmunopathologyJennifer K DeMarco, Joshua M Royal, William E Severson, et al.
Pageof 7